Reviewing Oncternal Therapeutics Inc. (ONCT)’s and OPKO Health Inc. (NASDAQ:OPK)’s results

Oncternal Therapeutics Inc. (NASDAQ:ONCT) and OPKO Health Inc. (NASDAQ:OPK), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Oncternal Therapeutics Inc. 6 0.00 N/A -1.29 0.00
OPKO Health Inc. 2 -0.31 408.83M -0.33 0.00

Table 1 demonstrates Oncternal Therapeutics Inc. and OPKO Health Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows Oncternal Therapeutics Inc. and OPKO Health Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oncternal Therapeutics Inc. 0.00% -104.2% -86.4%
OPKO Health Inc. 25,037,050,646.09% -10.7% -7.6%

Risk and Volatility

Oncternal Therapeutics Inc. is 87.00% more volatile than Standard and Poor’s 500 because the company has a beta of 1.87. From a competition point of view, OPKO Health Inc. has a 2.13 beta which is 113.00% more volatile compared to Standard and Poor’s 500.


The Current Ratio and a Quick Ratio of Oncternal Therapeutics Inc. are 12.4 and 12.4. Competitively, OPKO Health Inc. has 1.1 and 1 for Current and Quick Ratio. Oncternal Therapeutics Inc.’s better ability to pay short and long-term obligations than OPKO Health Inc.

Institutional and Insider Ownership

Institutional investors held 11.6% of Oncternal Therapeutics Inc. shares and 26.4% of OPKO Health Inc. shares. About 18.4% of Oncternal Therapeutics Inc.’s share are held by insiders. Competitively, 5.5% are OPKO Health Inc.’s share held by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Oncternal Therapeutics Inc. -11.67% -21.04% -41.04% -27.92% -95.95% -16.85%
OPKO Health Inc. -1.4% -14.57% -8.26% -43.28% -62.19% -29.9%

For the past year Oncternal Therapeutics Inc. was less bearish than OPKO Health Inc.


On 5 of the 9 factors OPKO Health Inc. beats Oncternal Therapeutics Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The companyÂ’s Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The companyÂ’s pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3-4 chronic kidney disease patients with vitamin D deficiency; and VARUBI for chemotherapy-induced nausea and vomiting. This segment is also developing TT401, which is in Phase II clinical trials for type 2 diabetes and obesity; TT701, an androgen receptor modulator that is in Phase II clinical trials for androgen deficiency indications; and hGH-CTP, a growth hormone injection that is in Phase III clinical trials. In addition, it engages in developing and commercializing hGH-CTP, a recombinant human growth hormone product that is in Phase III; developing Factor VIIa drug for hemophilia that is in Phase IIa, an NK-1 compound, and drugs for treating asthma and chronic obstructive pulmonary disease; developing and producing specialty active pharmaceutical ingredients; and discovery of drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, this segment engages in the development, manufacture, and sale of pharmaceutical, nutraceutical, and veterinary products; and markets and distributes pharmaceutical and natural products. Additionally, OPKO Health, Inc. operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was incorporated in 1991 and is headquartered in Miami, Florida.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.